{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T05:03:36Z","timestamp":1779685416818,"version":"3.53.1"},"reference-count":10,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to compare the clinical efficacy and safety of two rosacea treatment regimens: oral doxycycline plus the Shumin treatment instrument and oral doxycycline plus red light therapy. Objective assessments, including reflectance confocal microscopy, were used to evaluate both regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>A total of 60 patients with rosacea were randomly divided into two groups, each containing 30 patients. The control group received doxycycline (100\u202fmg\/day) orally combined with red light therapy for 12\u202fweeks (twice a week), whereas the experimental group received doxycycline (100\u202fmg\/day) orally combined with Shumin treatment instrument therapy for 12\u202fweeks (twice a week).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The efficacy rate was 93.3% in the experimental group and 80.0% in the control group. Following treatment, significant reductions in Dermatology Life Quality Index scores and Demodex counts were achieved in both groups (all\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001). However, the experimental group exhibited superior improvements in Dermatology Life Quality Index scores and affected hair follicle counts compared with the control group (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.05). No significant difference was observed in the reduction in the total\n                      <jats:italic>Demodex<\/jats:italic>\n                      count between the groups. Similarly, no significant difference was observed in the change in the total hair follicle number between the groups. Furthermore, the relapse rate was notably lower in the experimental group than in the control group (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.026).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>When used as an adjunctive therapy with oral doxycycline, the Shumin device yields better clinical outcomes than red light therapy for treating rosacea and has a favorable safety profile. These preliminary results establish a basis for the use of adjuvant physical interventions for rosacea.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1826076","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T04:35:46Z","timestamp":1779683746000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A clinical investigation using reflectance confocal microscopy to evaluate the add-on efficacy of the Shumin treatment instrument combined with doxycycline for rosacea"],"prefix":"10.3389","volume":"13","author":[{"given":"Yimin","family":"He","sequence":"first","affiliation":[{"name":"Department of Dermatology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengting","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1016\/j.jaad.2020.01.077","article-title":"Standard management options for rosacea: the 2019 update by the National Rosacea Society expert committee","volume":"82","author":"Thiboutot","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.jaad.2004.01.048","article-title":"Standard grading system for rosacea: report of the National Rosacea Society expert committee on the classification and staging of rosacea","volume":"50","author":"Wilkin","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"279","DOI":"10.35541\/cjd.20201078","article-title":"Guidelines for the diagnosis and treatment of rosacea in China (2021 edition)[J]","volume":"54","author":"Gu","year":"2021","journal-title":"Chin J Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/s0190-9622(99)70085-x","article-title":"A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea","volume":"40","author":"Maddin","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"659","DOI":"10.2147\/PPA.S345258","article-title":"Health related quality of life of rosacea patients in China assessed by dermatology life quality index and willingness to pay","volume":"16","author":"Huang","year":"2022","journal-title":"Patient Prefer Adherence"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1080\/17512433.2025.2550727","article-title":"Treatment management for rosacea: current pharmacological and non-pharmacological options","volume":"18","author":"Volk","year":"2025","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1007\/s10103-020-03200-1","article-title":"Laser and light-based therapies in the management of rosacea: an updated systematic review","volume":"36","author":"Husein-elahmed","year":"2021","journal-title":"Laser Med Sci"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.jid.2020.02.025","article-title":"Rosacea is characterized by a profoundly diminished skin barrier","volume":"140","author":"Medgyesi","year":"2020","journal-title":"J Invest Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1159\/000534245","article-title":"Evidence for the clinical association between Demodex and rosacea:a review","volume":"240","author":"Wei","year":"2024","journal-title":"Dermatology"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.2174\/1874467214666210210122628","article-title":"Minocycline and doxycycline: more than antibiotics","volume":"14","author":"Singh","year":"2021","journal-title":"Curr Mol Pharmacol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1826076\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T04:35:49Z","timestamp":1779683749000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1826076\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":10,"alternative-id":["10.3389\/fmed.2026.1826076"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1826076","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"article-number":"1826076"}}